Compugen Ltd. (NASDAQ:CGEN)’s share price was up 4.8% during mid-day trading on Friday . The company traded as high as $7.22 and last traded at $7.20, with a volume of 181,768 shares trading hands. The stock had previously closed at $6.87.

A number of equities analysts have recently weighed in on the company. FBR & Co restated a “buy” rating on shares of Compugen in a research note on Thursday, May 12th. Zacks Investment Research upgraded Compugen from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.25.

The stock’s market cap is $363.87 million. The company’s 50-day moving average is $6.65 and its 200-day moving average is $6.15.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. Analysts expect that Compugen Ltd. will post ($0.56) EPS for the current year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.